ALOS4

ALOS4 is a synthetic cyclic peptide originally identified through phage display for its ability to bind to the $\alpha v \beta 3$ integrin. Despite its initial isolation based on integrin binding, ALOS4 does not exhibit typical RGD-like functional activity in vitro. Instead, its potent antitumor effects, observed in preclinical models of melanoma, are attributed to a systemic anti-inflammatory mechanism. Specifically, ALOS4 has been shown to suppress type I interferon signaling in response to double-stranded RNA mimics and significantly alter the immune cell population infiltrating tumors. Developed through a collaboration between Ariel University and Roswell Park Comprehensive Cancer Center, ALOS4 has demonstrated a high safety profile in animal studies, with no signs of toxicity even at doses far exceeding efficacious levels.